FDA, Advisory Panel Agree: Post-Hoc Analyses Won't Fly
This article was originally published in The Gray Sheet
Executive Summary
CDRH's critique of Guidant's post-hoc analysis of its Contak CD data sends a clear warning to sponsors who attempt to draw positive conclusions about one subgroup from an inconclusive clinical trial.
You may also be interested in...
NMT STARFlex Single-Arm Study Insufficient For Approval, Panel Concludes
NMT Medical must conduct a randomized controlled trial of the STARFlex septal occlusion system to demonstrate that the device is superior to medical therapy in preventing strokes, FDA's Circulatory System Devices Panel concluded at its Sept. 10 meeting in Gaithersburg, Maryland
NMT STARFlex Single-Arm Study Insufficient For Approval, Panel Concludes
NMT Medical must conduct a randomized controlled trial of the STARFlex septal occlusion system to demonstrate that the device is superior to medical therapy in preventing strokes, FDA's Circulatory System Devices Panel concluded at its Sept. 10 meeting in Gaithersburg, Maryland
Medtronic InSync ICD Gains Panel Support In Tiebreaking 6-5 Vote
The recommended post-market requirement for Medtronic's InSync ICD and its pacing counterpart suggests that companies that conduct pivotal studies with a small number of patients will be expected to follow up with a large trial